Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Theriva Biologics Inc (AMEX: TOVX) was $0.44 for the day, down -2.45% from the previous closing price of $0.45. In other words, the price has decreased by -$2.45 from its previous closing price. On the day, 1.02 million shares were traded. TOVX stock price reached its highest trading level at $0.4515 during the session, while it also had its lowest trading level at $0.43.
Ratios:
Our analysis of TOVX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.19 and its Current Ratio is at 1.19. In the meantime, Its Debt-to-Equity ratio is 0.27 whereas as Long-Term Debt/Eq ratio is at 0.21.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TOVX now has a Market Capitalization of 4302762 and an Enterprise Value of -5031815.
Stock Price History:
The Beta on a monthly basis for TOVX is 0.53, which has changed by -0.6986301 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, TOVX has reached a high of $2.64, while it has fallen to a 52-week low of $0.37. The 50-Day Moving Average of the stock is 4.37%, while the 200-Day Moving Average is calculated to be -49.33%.
Shares Statistics:
TOVX traded an average of 864.12K shares per day over the past three months and 2484810 shares per day over the past ten days. A total of 9.60M shares are outstanding, with a floating share count of 9.50M. Insiders hold about 1.04% of the company’s shares, while institutions hold 7.94% stake in the company. Shares short for TOVX as of 1759190400 were 239896 with a Short Ratio of 0.28, compared to 1756425600 on 498199. Therefore, it implies a Short% of Shares Outstanding of 239896 and a Short% of Float of 2.5.
Earnings Estimates
. The current rating of Theriva Biologics Inc (TOVX) reflects the combined expertise of 1.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.37 and low estimates of -$0.37.
Analysts are recommending an EPS of between -$2.15 and -$2.15 for the fiscal current year, implying an average EPS of -$2.15. EPS for the following year is -$0.75, with 1.0 analysts recommending between -$0.75 and -$0.75.
